Medical News

[ NICE Improves Access To Drug Treatments For Psoriatic Arthritis ]

NICE Improves Access To Drug Treatments For Psoriatic Arthritis

The National Institute for Health and Clinical Excellence (NICE) has extended the range of drugs that NHS healthcare professionals can prescribe for people who have active and progressive psoriatic arthritis. In its updated guidance, NICE advises healthcare professionals to prescribe infliximab ( Remicade ), etanercept ( Enbrel ) or adalimumab ( Humira ) if: - The person has peripheral arthritis with three or more tender joints and three or more swollen joints, and - The psoriatic arthritis has not responded to adequate trials of at least two standard disease-modifying anti-rheumatic drugs (DMARDs), administered either individually or in combination. The NICE technology appraisal advises healthcare professionals to opt for the least expensive drug first within their healthcare setting, taking into account the associated administration costs, the required dose and its price per dose.

Starting From Scratch: Career Counseling To Young Patients Or Adolescents At Risk For Neurodermatitis

A child who can't stop scratching himself may well be suffering from atopic dermatitis, also known as neurodermatitis. Extreme irritability of the skin with a concomitant urge to scratch is typical of the disorder. The condition often appears during the first year of life and is on the increase in industrialized countries. The patient's skin becomes hypersensitive and reacts strongly to even mild irritation. A research team led by LMU's Dr. Astrid Peters and Professor Katja Radon has just published a longitudinal study which monitored the course of the disease in almost 4000 subjects from early childhood to adulthood. The participants also supplied information regarding atopic reactions and occupational exposure to possible sensitizing agents. "Based on the data we obtained, we developed a probabilistic model that can predict the progress of the disorder during puberty, a phase which is often critical", says Radon.

Multinational Pristine Trial Findings Demonstrate Burden Of Moderate-To-Severe Plaque Psoriasis, And The Efficacy Profile Of Etanercept Treatment

Data from a multinational study demonstrate that etanercept effectively treats moderate-to-severe plaque psoriasis, with a significant mean improvement from baseline in Psoriasis Area and Severity Index (PASI) of up to 82 percent at week 24.1 The findings, presented at the 40th Annual European Society for Dermatological Research (ESDR) meeting, are from the PRISTINE (PsoRiasis study to assess effIcacy and SafeTy IN subjects taking Etanercept 50 mg once weekly and twice weekly with adjunct therapy) trial, a multi-center, randomized, double-blind study evaluating the efficacy and safety of two dose regimens of etanercept used with adjunctive topical therapies.2 With more than 18 years of collective clinical experience, etanercept offers physicians and patients an established efficacy and safety profile in managing several inflammatory diseases.

Rheumatoid Arthritis And Psoriasis Sections Launched On Medical News Today

We are pleased to announce the launch of two new patient information sections on Medical News Today, one on Rheumatoid Arthritis and the other about Psoriasis. The sections contain the following information: Rheumatoid Arthritis Information Hub What is Rheumatoid Arthritis (RA)? Signs and symptoms of RA RA risk factors Causes of RA RA Diagnosis Treatment for RA RA complications Psoriasis Information Hub What is Psoriasis? Types of Psoriasis Signs and symptoms of Psoriasis Psoriasis risk factors Causes of Psoriasis Psoriasis triggers Psoriasis Diagnosis Treatment for Psoriasis Psoriasis complications What is Psoriatic Arthritis? For more information please contact us. About MediLexicon International Limited Medilexicon International Limited is a UK company which owns four websites: Medical News Today Medical News Today is the largest independent health and medical news website on the Internet.

Loop PR: DreamSkin Health Ltd: World First In Eczema Treatment

Following five years of research and development, Dreamskin Health Ltd is proud to have launched the world's first range of hydrating, medical-grade silk garments designed to relieve the itching and irritation of eczema and dermatitis. The secret to the new garments is a proprietary biomimetic copolymer matrix which is firmly bound to the surface of the silk and assists the water and temperature regulation functions of the skin. "The Dreamskin(R) polymer is a major benefit for patients", said Technical Director, Howard Cairns. "We were inspired by looking at how the hydration of modern contact lenses is achieved and realised we could use our fabric engineering knowledge to produce a similar effect in fabric." Dreamskin(R) garments are currently available in bodysuits for babies and face masks, tops, leggings and pyjamas for children up to 12 years old and are designed with wearer comfort as the top consideration.

Fast: [10]

Medical News © Nanda
Designer Damodar